Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors

Cancer Research

Volumn 62, Issue 10, 2002, Pages 2856-2860

  Qin, Zhihai ^a   Harders, Christina ^b   Cao, Xuetao ^c   Huber, Christoph ^b   Blankenstein, Thomas ^a,d   Seliger, Barbara ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSPORTER FOR ANTIGEN PRESENTATION 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CARCINOGENICITY; CELL TRANSFORMATION; CYTOKINE PRODUCTION; FIBROBLAST; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION;

3T3 CELLS; ANIMALS; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; FEMALE; INTERFERON TYPE II; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; SPLEEN; T-LYMPHOCYTES; TRANSFECTION;

EID: 0037093279     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Loss of HLA class 1 antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
2. Antigen-processing machinery breakdown and tumor growth
3. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway
4. Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters
5. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter
6. Mechanisms of MHC class I-restricted antigen processing
7. Genes regulating MHC class I processing of antigen
8. Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells
9. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines
10. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis
11. Suppression of MHC class I antigens in oncogenic transformants: Association with decreased recognition by cytotoxic T lymphocytes
12. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts
13. TAP expression provides a general method for improving the recognition of malignant cells in vivo
14. IFNγ lymphocytes prevent primary tumour development and shape tumour immunogenicity
15. Tumor immunology: The glass is half full
16. The makings of a tumor rejection antigen
17. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
18. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: Implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines
19. Cross-presentation, dendritic cells, tolerance and immunity
20. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer
21. Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes
22. Genetic approaches to cancer immunotherapy
23. Strategies for immunotherapy of cancer
24. Immunotherapy of human cancer: Lessons from mice
25. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene
26. Rejection of mouse sarcoma cells after transfection of MHC class II genes
27. 7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
28. Vaccinations with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant
29. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants
30. Tumor cells cotransfected with interleukin-7 and B7.I genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines
31. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation
32. Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene
33. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target
34. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells
35. Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses
36. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells
37. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay